- Details
- Description
-
Packaging Size1Bottle/Box
-
Strength40mg/1ml
-
CompositonToripalimab (特瑞普利单抗)
-
TreatmentNasopharyngeal Carcinoma (NPC)
-
FormInjection
-
BrandLoqtorzi (拓益)
-
Quantity Unit240mg*6ml/Bottle/Box
-
ManufacturerJunshi Biosciences,China
Loqtorzi (toripalimab-tpzi) sold under the brand name 拓益 in china, is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.
On October 27, 2023, The FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).
FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
